Indivior Reports Strong FY25 Earnings, Completes US Domestication, and Resolves Major Opioid Litigation

summarizeSummary

Indivior reported a strong financial rebound in FY25 with significant net income growth, completed its U.S. domestication, and resolved major opioid litigation, while also disclosing new dental litigation and a prior period financial restatement.

check_boxKey Events

• Strong Financial Performance in FY25

  Net revenue increased 4% to $1,239 million, operating income surged 594% to $262 million, and net income rose significantly to $210 million ($1.64 diluted EPS) for the fiscal year ended December 31, 2025. SUBLOCADE sales grew 13% to $856 million, now representing 69% of net revenue.

• US Domestication Completed

  The company completed its U.S. domestication on January 23, 2026, with Indivior Pharmaceuticals, Inc. (Delaware) becoming the ultimate parent company. This corporate reorganization was accounted for as a common-control transaction in Q1 2026, as previously announced in an 8-K filing on 2026-01-26.

• Major Litigation Overhangs Resolved

  Indivior prepaid the remaining $295 million DOJ liability in November 2025 and paid the final $25 million antitrust settlement in 2025. The Opioid MDL settlement was finalized in January 2026, with an $80 million accrual as of December 31, 2025, resolving claims from 49 states and tribal nations.

• Strategic Restructuring and Product Exits

  The company initiated its 'Indivior Action Agenda' in August 2025, incurring $127 million in restructuring charges. This included exiting several non-U.S. markets and discontinuing marketing for PERSERIS (July 2024) and OPVEE (Q3 2025), with expected reductions in 2026 operating expenses.

auto_awesomeAnalysis

Indivior Pharmaceuticals, Inc. reported a significant financial turnaround for fiscal year 2025, with net income reaching $210 million compared to $7 million in 2024, and diluted EPS increasing to $1.64 from $0.05. This performance was primarily driven by a 13% growth in SUBLOCADE sales, which now accounts for 69% of net revenue. The company also completed its U.S. domestication in January 2026, a strategic corporate reorganization. Furthermore, Indivior resolved several major legal overhangs, including prepaying the remaining $295 million DOJ liability and finalizing the Opioid MDL settlement for $80 million, which covers claims from 49 states and tribal nations. However, the company faces ongoing challenges, including negative cash flow from operations ($27 million used in 2025), negative working capital, and substantial new dental litigation involving approximately 2,000 cases and 25,000 plaintiffs, for which no loss estimate can currently be made. Strategic restructuring initiatives in 2025, including exiting several non-U.S. markets and discontinuing marketing for PERSERIS and OPVEE, resulted in $127 million in charges but are expected to lead to lower operating expenses in 2026. The company also restated prior period financials for 2024 and 2023 to correct an error in the Branded Fee accrual, which materially impacted reported net income for 2024.